Chris Whitehead, managed platform product manager at SolutionsPT, looks at the importance of disaster resilience and the solutions available to help protect pharmaceutical manufacturers from the loss of critical data and interruptions to production.
Clocks
Changes to IP protection laws have left pharmaceutical manufacturers facing fierce competition and urgently looking for ways to streamline production, boost productivity and minimise downtime whilst adhering to a strict regulatory framework. With many pharmaceutical plants now moving towards continuous operation, the threat of disruption to production looms large and is costlier than ever before.
Unlike other industries, pharma has not always had to pay close attention to manufacturing costs. With generous margins and limited competition, the high price tag of finished drugs often compensated for any inefficiencies in production. However, the intellectual property (IP) landscape in pharmaceuticals has changed. New competitors are emerging, increasing the pressure on manufacturers to fast-track new drug innovation, increase the speed at which they introduce new drugs to market and claw back profits with improved margins and better operational efficiency.